KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Jul 31, 2025. Filed Sep 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jul 31, 2025 · Filed Sep 12, 2025
KMTS$29.55-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended July 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(25,826) | $(20,323) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,028 | 2,375 |
| Loss on disposal of property and equipment | 280 | 255 |
| Reserve for lost medical supplies | 412 | (33) |
| Provision for uncollectible accounts receivable | 613 | 706 |
| Interest paid-in-kind | — | 233 |
| Amortization of debt discounts and issuance costs | 469 | 200 |
| Share-based compensation expense | 4,579 | 377 |
| Non-cash lease expense | 61 | 152 |
| Change in fair value of warrant liabilities | (2,909) | — |
| Changes in operating assets and liabilities: | ||
| Disposable medical equipment supplies | (460) | (599) |
| Prepaid expenses and other current assets | 140 | (389) |
| Accounts receivable | (1,777) | (2,890) |
| Accounts payable | (2,896) | 2,265 |
| Accrued liabilities | (860) | 140 |
| Operating lease liabilities | (138) | 22 |
| Other long-term assets | 10 | 10 |
| Net cash used in operating activities | (26,274) | (17,499) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (8,166) | (7,037) |
| Deposits for medical rental equipment | (103) | (20) |
| Refund of deposits for medical rental equipment | 37 | 23 |
| Net cash used in investing activities | (8,232) | (7,034) |
| Cash flows from financing activities | ||
| Proceeds from issuance of redeemable preferred stock | — | 103,400 |
| Proceeds from issuance of stock to non-controlling interest | — | 17,100 |
| Deemed dividend for payments to third party on behalf of shareholder | — | (1,023) |
| Payment of equity issuance costs | — | (3,224) |
| Payments of IPO offering costs | (1,875) | — |
| Net cash provided by (used in) financing activities | (1,875) | 116,253 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (36,381) | 91,720 |
| Cash, cash equivalents and restricted cash | ||
| Beginning of period | 237,929 | 8,583 |
| End of period | $201,548 | $100,303 |
| Reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $201,214 | $99,969 |
| Restricted cash | 334 | 334 |
| Cash, cash equivalents and restricted cash | $201,548 | $100,303 |
| Non-cash investing and financing activities: | ||
| Purchases of property and equipment in accrued liabilities and accounts payable | $6,900 | 8,499 |
| Supplemental disclosure of cash flow information | ||
| Income taxes refunds received | $(39) | $— |
| Interest paid | 1,423 | 1,220 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.